|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al National Cancer Institute of Canada Clinical Trials Group:
Erlotinib in previously treated non-small-cell lung cancer. N Engl
J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Braiteh F, Kurzrock R and Johnson FM:
Trichomegaly of the eyelashes after lung cancer treatment with the
epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol.
26:3460–3462. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeon SH, Ryu JS, Choi GS, et al: Erlotinib
induced trichomegaly of the eyelashes. Tuberc Respir Dis (Seoul).
74:37–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khozin S, Blumenthal GM, Jiang X, et al:
U.S. Food and Drug Administration approval summary: Erlotinib for
the first-line treatment of metastatic non-small cell lung cancer
with epidermal growth factor receptor exon 19 deletions or exon 21
(L858R) substitution mutations. Oncologist. 19:774–779. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gray H: Trichomegaly or movie lashes.
Stanford Med Bull. 2:157–158. 1944.
|
|
8
|
Oliver GL and McFarlane DC: Congenital
trichomegaly: With associated pigmentary degeneration of the
retina, dwarfism, and mental retardation. Arch Ophthalmol.
74:169–171. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kline AD, Krantz ID, Sommer A, et al:
Cornelia de Lange syndrome: Clinical review, diagnostic and scoring
systems and anticipatory guidance. Am J Med Genet A.
143A:1287–1296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ziakas NG, Jogiya A and Michaelides M: A
case of familial trichomegaly in association with oculocutaneous
albinism type 1. Eye (Lond). 18:863–864. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen PR, Escudier SM and Kurzrock R:
Cetuximab-associated elongation of the eyelashes: Case report and
review of eyelash trichomegaly secondary to epidermal growth factor
receptor inhibitors. Am J Clin Dermatol. 12:63–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pascual JC, Bañuls J, Belinchon I, Blanes
M and Massuti B: Trichomegaly following treatment with gefitinib
(ZD1839). Br J Dermatol. 151:1111–1112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pucci N, Novembre E, Lombardi E, et al:
Long eyelashes in a case series of 93 children with vernal
keratoconjunctivitis. Pediatrics. 115:e86–e91. 2005.PubMed/NCBI
|
|
14
|
Alpsoy E: Hypotrichosis, long eyelashes
and atopic dermatitis: A new syndrome? J Eur Acad Dermatol
Venereol. 18:374–375. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carser JE and Summers YJ: Trichomegaly of
the eyelashes after treatment with erlotinib in non-small cell lung
cancer. J Thorac Oncol. 1:1040–1041. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iacovelli R, Palazzo A, Trenta P, et al:
Trichomegaly of the eyelashe induced by erlotinib therapy. Lung
Cancer. 64 (Suppl 1):S59–2009. View Article : Google Scholar
|
|
17
|
Lane K and Goldstein SM:
Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg.
23:65–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vergou T, Stratigos AJ, Karapanagiotou EM,
et al: Facial hypertrichosis and trichomegaly developing in
patients treated with the epidermal growth factor receptor
inhibitor erlotinib. J Am Acad Dermatol. 63:e56–e58. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirsch FR and Bunn PA Jr: EGFR testing in
lung cancer is ready for prime time. Lancet Oncol. 10:432–433.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller VA, Riely GJ, Zakowski MF, et al:
Molecular characteristics of bronchioloalveolar carcinoma and
adenocarcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small-cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petrelli F, Borgonovo K, Cabiddu M, Lonati
V and Barni S: Relationship between skin rash and outcome in
non-small-cell lung cancer patients treated with anti-EGFR tyrosine
kinase inhibitors: A literature-based meta-analysis of 24 trials.
Lung Cancer. 78:8–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bouché O, Brixi-Benmansour H, Bertin A,
Perceau G and Lagarde S: Trichomegaly of the eyelashes following
treatment with cetuximab. Ann Oncol. 16:1711–1712. 2005. View Article : Google Scholar
|
|
26
|
Shah NT, Kris MG, Pao W, et al: Practical
management of patients with non-small-cell lung cancer treated with
gefitinib. J Clin Oncol. 23:165–174. 2005. View Article : Google Scholar : PubMed/NCBI
|
